Indocid

Legal status and availability in the UK

Indometacin (indomethacin) is a prescription-only medicine (POM) in the UK.

In our online pharmacy, Indocid is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.

Basic Indocid information

• INN (international nonproprietary name): Indometacin (also known as indomethacin)
• Brand names available in the United Kingdom: Indocid; generic indometacin
• ATC code: M01AB01 (Anti-inflammatory and antirheumatic products, non-steroids; acetic acid derivatives and related substances).
• Forms and dosages: capsules/tablets 25 mg and 50 mg, sustained‑release 75 mg, oral suspension 25 mg/5 mL, suppositories 50 mg and 100 mg, injectable 1 mg/vial (lyophilised) for IV reconstitution.
• Registration status in the United Kingdom: listed with the MHRA
• OTC / Rx classification: Prescription only (Rx)

Clinical effectiveness in the United Kingdom

Indometacin remains effective for acute gout flares and some rheumatological indications when given at guideline doses.

In NHS practice indometacin is often reserved for patients needing rapid symptom control or where other NSAIDs are not suitable.

Standard adult doses recorded in practice include 50 mg three times daily for acute gout and 25–50 mg two to three times daily for arthritis, with a maximum recommended daily dose of 200 mg.

UK clinicians balance efficacy with risk and typically start older patients at lower doses while monitoring renal function and blood pressure.

Indications and expanded uses (MHRA and NHS practice)

Licensed indications in the UK include symptomatic treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute gouty arthritis.

Intravenous formulations are used in hospital settings for specific uses, such as neonatal PDA closure under specialist care.

NHS practice documents occasional off‑label specialist use in paediatric rheumatology under consultant oversight with weight‑based dosing and documented rationale.

Absolute contraindications include active gastrointestinal bleeding, severe hepatic, renal or cardiac failure, and NSAID hypersensitivity.

UK prescribers must obtain informed consent and document the rationale when using indomethacin off‑label, particularly for younger or frail patients.

• MHRA-approved uses: Symptomatic treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute gouty arthritis.
• Off-label specialist uses: Select paediatric rheumatology indications under consultant supervision and with weight-based dosing.
• Prescriber checklist: Indication, dose, monitoring plan, patient information and documented consent for off‑label use.

Composition and brand landscape (UK focus)

The active ingredient is indomethacin (INN) with ATC code M01AB01 and is commonly supplied as generics in the UK.

Brands include Indocid, while most supply comes from generic manufacturers.

Available forms include 25 mg and 50 mg tablets or capsules, sustained‑release 75 mg, suppositories (50 mg and 100 mg), oral suspension 25 mg/5 mL and IV 1 mg/vial.

Hospital trusts may hold injectable stocks for specialist inpatient use, while community pharmacies dispense tablet and suspension forms where prescribed.

When patients ask about generic versus branded versions, pharmacists can reassure them about bioequivalence.

Contraindications and special precautions

Absolute contraindications include hypersensitivity to indomethacin or other NSAIDs, active peptic ulceration or GI bleeding, severe hepatic, renal or cardiac insufficiency, and aspirin‑exacerbated respiratory disease.

Special precautions are required for older adults where clinicians start at lower doses and monitor renal and cardiovascular function closely.

Indomethacin should be avoided in later pregnancy because of risk of premature closure of the fetal ductus arteriosus and used cautiously in breastfeeding after risk/benefit assessment.

Advise patients to limit alcohol intake and to be cautious with driving or operating machinery if they experience dizziness or visual disturbance.

• Pharmacy counselling checklist: Confirm contraindications, review current medicines, advise on alcohol and driving, and plan monitoring for BP and renal function.
• Contraindication categories: Hypersensitivity, active GI bleed, severe organ failure, NSAID‑induced asthma.

Dosage guidelines (NHS‑aligned)

For osteoarthritis, rheumatoid arthritis and ankylosing spondylitis start at 25 mg two to three times daily and increase by 25–50 mg as tolerated with a maximum of 200 mg per day.

For acute gout the usual approach is 50 mg three times daily until relief, using the lowest effective dose for the shortest practical duration.

Elderly patients and those with renal or hepatic impairment should start at the lower end of the dosing range with frequent monitoring.

Paediatric dosing is specialist-led and weight-based and is not routine in primary care.

Pharmacists should give clear advice on taking tablets with food to reduce GI upset.

Interactions overview (MHRA Yellow Card and UK practice)

Key interactions reported include increased bleeding risk with anticoagulants and reduced antihypertensive efficacy with ACE inhibitors, ARBs and diuretics.

Indomethacin can raise lithium and methotrexate levels and has additive renal risk when combined with other nephrotoxic drugs.

Concurrent corticosteroids or selective serotonin reuptake inhibitors can increase GI bleeding risk.

Advise patients to avoid combining multiple NSAIDs and to report any signs of bleeding or new swelling to their GP or pharmacist.

• High-risk drug classes: Anticoagulants, diuretics, ACE inhibitors/ARBs, lithium, methotrexate, corticosteroids, SSRIs.
• Pharmacy interaction matrix: Check for duplicated NSAID exposure, flag anticoagulant co-prescriptions, and encourage Yellow Card reporting for suspected adverse reactions.

Comparable medicines and prescribing preferences (NHS alternatives)

NHS clinicians often favour naproxen or diclofenac as alternatives depending on the patient’s cardiovascular and gastrointestinal risk profile.

COX‑2 selective agents such as celecoxib are considered when GI protection is required, noting their different safety profile.

Comparative effectiveness in UK practice suggests similar analgesia across many NSAIDs, with differing tolerability and risk considerations guiding choice.

When explaining choices to patients, clinicians should cover monitoring plans and deprescribing options.

Frequently asked questions

• How quickly will indomethacin work for a gout attack? Pain relief is often noticeable within 2–4 hours and many patients improve substantially within 3–5 days.
• Can I take indomethacin if I’m on blood pressure tablets? Caution is required because NSAIDs can reduce some antihypertensives’ effectiveness and increase renal risk; review with GP or pharmacist is advised.
• Is indomethacin safe for long‑term use? Long‑term use raises gastrointestinal, renal and cardiovascular risks and NHS guidance recommends the lowest effective dose for the shortest period with regular review.
• Can I drink alcohol while taking indomethacin? Heavy alcohol should be avoided as it increases the risk of GI bleeding and liver strain.

When to contact the GP or NHS 111: seek urgent advice for severe abdominal pain, black stools, marked shortness of breath, new swelling or signs of an allergic reaction.

Guidelines for proper use (pharmacy counselling and NHS support)

Counselling should explain the indication, expected time to benefit, dosing schedule and missed-dose rules.

Patients should be warned about side effects to watch for, including GI pain, black stools, dizziness and severe rash.

Pharmacists must review interactions with anticoagulants, lithium, methotrexate and antihypertensives and advise appropriate monitoring for BP, renal and liver function.

Provide written advice, link to NHS.uk pages and update the NHS Summary Care Record or Electronic Prescription Service entry when possible.

• Pharmacy staff checklist: Confirm indication, confirm current medicines, give storage advice (store below 30°C), provide written leaflet and advise on disposal of unused tablets.

Delivery across the United Kingdom